- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 756302, 11 pages
Promoter Hypermethylation of the EMP3 Gene in a Series of 229 Human Gliomas
1Neuro-Bio-Oncology Center, Policlinico di Monza Foundation (Vercelli)/Consorzio di Neuroscienze, University of Pavia, Via Pietro Micca, 29, 13100 Vercelli, Italy
2Department of Medical Sciences, University of Turin, Via Santena 7, 10126 Turin, Italy
Received 17 May 2013; Revised 26 June 2013; Accepted 10 July 2013
Academic Editor: Akira Matsuno
Copyright © 2013 Marta Mellai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- V. Taylor, A. A. Welcher, A. E. Program, and U. Suter, “Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family,” The Journal of Biological Chemistry, vol. 270, no. 48, pp. 28824–28833, 1995.
- V. Taylor and U. Suter, “Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family,” Gene, vol. 175, no. 1-2, pp. 115–120, 1996.
- I. Ben-Porath and N. Benvenisty, “Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteins,” Gene, vol. 183, no. 1-2, pp. 69–75, 1996.
- T. Liehr, G. Kuhlenbäumer, P. Wulf et al., “Regional localization of the human epithelial membrane protein genes 1, 2, and 3 (EMP1, EMP2, EMP3) to 12p12.3, 16p13.2, and 19q13.3,” Genomics, vol. 58, no. 1, pp. 106–108, 1999.
- M. Alaminos, V. Dávalos, S. Ropero et al., “EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma,” Cancer Research, vol. 65, no. 7, pp. 2565–2571, 2005.
- B. Tews, J. Felsberg, C. Hartmann et al., “Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling,” International Journal of Cancer, vol. 119, no. 4, pp. 792–800, 2006.
- A. Kunitz, M. Wolter, J. van den Boom et al., “DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in human gliomas,” Brain Pathology, vol. 17, no. 4, pp. 363–370, 2007.
- K. K. W. Li, J. C.-S. Pang, N. Y.-F. Chung et al., “EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q,” International Journal of Cancer, vol. 120, no. 4, pp. 947–950, 2007.
- C. D. E. Margetts, M. Morris, D. Astuti et al., “Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma,” Endocrine-Related Cancer, vol. 15, no. 3, pp. 777–786, 2008.
- S. Fumoto, K. Tanimoto, E. Hiyama, T. Noguchi, M. Nishiyama, and K. Hiyama, “EMP3 as a candidate tumor suppressor gene for solid tumors,” Expert Opinion on Therapeutic Targets, vol. 13, no. 7, pp. 811–822, 2009.
- S. Fumoto, K. Hiyama, K. Tanimoto et al., “EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma,” Cancer Letters, vol. 274, no. 1, pp. 25–32, 2009.
- W. Zhou, Z. Jiang, X. Li et al., “EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations,” Journal of Korean Medical Science, vol. 24, no. 1, pp. 97–103, 2009.
- Z. Jiang, W. Zhou, X.-G. Li et al., “The methylation analysis of EMP3 and PCDH-gamma-A11 gene in human glioma,” Zhonghua Wai Ke Za Zhi, vol. 48, no. 4, pp. 300–304, 2010.
- C. A. Scrideli, C. G. Carlotti Jr., O. K. Okamoto et al., “Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR,” Journal of Neuro-Oncology, vol. 88, no. 3, pp. 281–291, 2008.
- A. Ernst, S. Hofmann, R. Ahmadi et al., “Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival,” Clinical Cancer Research, vol. 15, no. 21, pp. 6541–6550, 2009.
- S. Zheng, E. A. Houseman, Z. Morrison et al., “DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression,” Neuro-Oncology, vol. 13, no. 3, pp. 280–289, 2011.
- A. Pasini, P. Iorio, E. Bianchi, et al., “LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation,” Oncology Reports, vol. 28, no. 6, pp. 2271–2277, 2012.
- D. N. Louis, H. Ohgaki, O. D. Wiestler, et al., WHO Classification of Tumors of the Central Nervous Systems, International Agency for Research on Cancer (IARC), Lyon, France, 4th edition, 2007.
- M. Mellai, V. Caldera, L. Annovazzi et al., “MGMT promoter hypermethylation in a series of 104 glioblastomas,” Cancer Genomics and Proteomics, vol. 6, no. 4, pp. 219–227, 2009.
- M. Esteller, S. R. Hamilton, P. C. Burger, S. B. Baylin, and J. G. Herman, “Inactivation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia,” Cancer Research, vol. 59, no. 4, pp. 793–797, 1999.
- M. Mellai, O. Monzeglio, A. Piazzi et al., “MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors,” Journal of Neuro-Oncology, vol. 107, no. 3, pp. 617–631, 2012.
- M. Mellai, A. Piazzi, V. Caldera et al., “IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors,” Journal of Neuro-Oncology, vol. 105, no. 2, pp. 345–357, 2011.
- V. Caldera, M. Mellai, L. Annovazzi et al., “Antigenic and genotypic similarity between primary glioblastomas and their derived neurospheres,” Journal of Oncology, vol. 2011, Article ID 314962, 16 pages, 2011.
- M. Mellai, V. Caldera, L. Annovazzi, and D. Schiffer, “The distribution and significance of IDH mutations in gliomas,” in Evolution of the Molecular Biology of Brain Tumors and Therapeutic Implications, T. Lichtor, Ed., pp. 299–342, InTech, Rjieka, Croatia, 2013.
- H. Noushmehr, D. J. Weisenberger, K. Diefes et al., “Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma,” Cancer Cell, vol. 17, no. 5, pp. 510–522, 2010.
- B. Malzkorn, M. Wolter, M. J. Riemenschneider, and G. Reifenberger, “Unraveling the glioma epigenome-from molecular mechanisms to novel biomarkers and therapeutic targets,” Brain Pathology, vol. 21, no. 6, pp. 619–632, 2011.
- B. C. Christensen, A. A. Smith, S. Zheng et al., “DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma,” Journal of the National Cancer Institute, vol. 103, no. 2, pp. 143–153, 2011.
- J. Laffaire, S. Everhard, A. Idbaih et al., “Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis,” Neuro-Oncology, vol. 13, no. 1, pp. 84–98, 2011.
- S. Turcan, D. Rohle, A. Goenka et al., “IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype,” Nature, vol. 483, no. 7390, pp. 479–483, 2012.
- M. J. van den Bent, L. A. Gravendeel, T. Gorlia et al., “A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951,” Clinical Cancer Research, vol. 17, no. 22, pp. 7148–7155, 2011.
- J. Felsberg, N. Thon, S. Eigenbrod et al., “Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas,” International Journal of Cancer, vol. 129, no. 3, pp. 659–670, 2011.
- H. Ohgaki, B. Schauble, A. zur Hausen, K. von Ammon, and P. Kleihues, “Genetic alterations associated with the evolution and progression of astrocytic brain tumours,” Virchows Archiv, vol. 427, no. 2, pp. 113–118, 1995.
- J. Mora, N.-K. V. Cheung, L. Chen, J. Qin, and W. Gerald, “Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma,” Clinical Cancer Research, vol. 7, no. 5, pp. 1358–1361, 2001.
- C. Bettegowda, N. Agrawal, Y. Jiao et al., “Mutations in CIC and FUBP1 contribute to human oligodendroglioma,” Science, vol. 333, no. 6048, pp. 1453–1455, 2011.
- S. Yip, Y. S. Butterfield, O. Morozova et al., “Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers,” Journal of Pathology, vol. 226, no. 1, pp. 7–16, 2012.
- F. Sahm, C. Koelsche, J. Meyer, et al., “CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas,” Acta Neuropathologica, vol. 123, no. 6, pp. 853–860, 2012.
- H. Yan, D. W. Parsons, G. Jin et al., “IDH1 and IDH2 mutations in gliomas,” The New England Journal of Medicine, vol. 360, no. 8, pp. 765–773, 2009.
- M. J. van den Bent, H. J. Dubbink, Y. Marie et al., “IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group,” Clinical Cancer Research, vol. 16, no. 5, pp. 1597–1604, 2010.
- H. Colman, L. Zhang, E. P. Sulman et al., “A multigene predictor of outcome in glioblastoma,” Neuro-Oncology, vol. 12, no. 1, pp. 49–57, 2010.